Related Experiment Video
Updated: Aug 11, 2026

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
CD19+ B-cells in autoantibody-negative limbic encephalitis
Niels Hansen1, Demet Önder2, Kerstin Schwing2
1Department of Epileptology, University of Bonn Medical Center, Venusberg - Campus 1, 53127 Bonn, Germany; Department of Psychiatry and Psychotherapy, University Medicine Goettingen, Von-Siebold-Str. 5, 37075 Goettingen, Germany.
Insights
Increased CD19+ B-cells in cerebrospinal fluid (CSF) and blood-brain barrier impairment are observed in antibody-negative limbic encephalitis (LE). Further research is needed to understand the role of these B-cells in central nervous system (CNS) immunity and treatment strategies.
Area of Science:
- Neuroimmunology
- Cellular immunology
- Epileptology
Background:
- Temporal lobe epilepsy (TLE) can be caused by limbic encephalitis (LE), a condition with varying immunological profiles.
- Understanding the immune mechanisms in different LE subtypes is crucial for targeted therapies.
Purpose of the Study:
- To investigate the cellular immune repertoire in patients with TLE due to LE, differentiating between antibody-negative and antibody-associated LE.
- To explore the potential of flow cytometry in identifying biomarkers for subtype-specific treatment strategies.
Main Methods:
- Flow cytometry was used to analyze peripheral blood (PB) and cerebrospinal fluid (CSF) immune cells in 62 TLE patients with LE.
- Patients were categorized into antibody-negative LE (n=40) and neural autoantibody-positive LE (n=22).
- Neuropsychological testing, MRI, and EEG were also performed.
Main Results:
- CD19+ B-cells were significantly elevated in the PB and CSF of antibody-negative LE patients compared to those with intracellular antibody-positive LE.
- Impaired blood-brain barrier function was more prevalent in antibody-negative LE.
- No significant differences were found in other measured immune cell subsets (CD138+, CD4+, CD8+, HLA-DR+ cells) between LE groups.
Conclusions:
- Elevated CD19+ B-cells and blood-brain barrier dysfunction in antibody-negative LE suggest their involvement in the disease.
- The exact pathogenic role of these B-cells in central nervous system (CNS) immunity remains unclear due to a lack of correlation with clinical parameters.
- Further studies are warranted to assess the utility of CD19+ B-cells as biomarkers for treatment stratification in LE.
Purpose:
Flow cytometry helps to elucidate the cellular immune repertoire's mechanisms in patients with temporal lobe epilepsy (TLE) due to limbic encephalitis (LE) subcategories and carries potential significance for subtype-specific treatment.
Methods:
We enrolled 62 patients with TLE due to LE associated with no autoantibodies (n = 40), neural autoantibodies (n = 22), as well as autoantibodies against intracellular antigens (n = 15/22). All patients underwent neuropsychological testing, brain magnetic resonance imaging (MRI), electroencephalography (EEG) recordings, and peripheral blood (PB) and cerebrospinal fluid (CSF) investigations including flow cytometry.
Results:
CD19+ B-cells were increased in the PB and CSF of patients with antibody-negative LE compared with those associated with antibodies against intracellular antigens (Kruskal-Wallis one way analysis of variance (ANOVA) on ranks with Dunn's test, p < 0.05). There were no differences in CD138+ B-cells, CD4+ T-cells, human leukocyte antigen - DR isotype (HLA-DR+) CD4+ T-cells, CD8+ T-cells, and HLA-DR+ CD8+ T-cells in the CSF between groups with LE. The blood-brain barrier is more often impaired in patients with antibody-negative LE than in LE with antibodies against intracellular antigens (chi-square test, p < 0.05). In addition, we detected no correlations between immune cell subsets and clinical or paraclinical parameters in patients with antibody-negative and intracellular antibody-positive LE.
Conclusions:
The increase of CD19+ B-cells in the CSF and frequent signs of dysfunctional blood-brain barrier in patients with antibody-negative rather than intracellular antibody-positive LE suggest that CD19+ B-cells play a role in antibody-negative encephalitis although their pathogenic role in the central nervous system (CNS) immunity because of missing correlations between immune cells and clinical and paraclinical parameters remains unknown. Further studies are required to evaluate the usefulness of these B-cells as a biomarker for the stratification of treatment strategies.
More Related Videos
Related Concept Videos
Arboviral Encephalitis
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology

